학술논문

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib
Document Type
Correspondence
Source
In Blood 5 December 2019 134(23):2107-2111
Subject
Language
ISSN
0006-4971